Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Androgen deprivation therapy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    181 result(s) found for: Androgen deprivation therapy. Displaying page 1 of 10.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2018-004853-26 Sponsor Protocol Number: T315/2018 Start Date*: 2019-03-25
    Sponsor Name:Turku University Hospital
    Full Title: The effect of androgen deprivation therapy on the expression of prostate specific membrane antigen (PSMA) in treatment naive metastatic prostate cancer
    Medical condition: Metastatic prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071119 Hormone-dependent prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002415-10 Sponsor Protocol Number: PROCoMBO Start Date*: 2014-02-11
    Sponsor Name:University Medical Center Groningen
    Full Title: [18F]-labelled FDHT in PET/CT for detection and staging of bone metastases in hormone naïve prostate cancer
    Medical condition: Hormone naive prostate cancer, metastasized to bone (2 or more bone metastases).
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002815-20 Sponsor Protocol Number: MET07 Start Date*: 2007-10-09
    Sponsor Name:Royal Surrey County Hospital
    Full Title: A Prospective Randomised Pilot Study of Metformin and Lifestyle Intervention in the Prevention of Metabolic Syndrome due to Androgen Deprivation Therapy in Prostate Cancer
    Medical condition: Patients with prostate cancer on androgen deprivation therapy (ADT). Randomisation between standard treatment with ADT only, and the additional use of metformin with dietary and exercise advice. Ai...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001186 Adenocarcinoma of prostate LLT
    9.1 10052066 Metabolic syndrome LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-019004-24 Sponsor Protocol Number: PON-PC-02 Start Date*: 2010-04-30
    Sponsor Name:AZIENDA OSPEDALIERA S. LUIGI GONZAGA
    Full Title: ANDROGEN DEPRIVATION THERAPY WITHDRAWAL VERSUS MAINTENANCE AND INTERMITTENT DOCETAXEL THERAPY VERSUS CONTINUOUS ADMINISTRATION IN PATIENTS WITH PROSTATE CANCER RESISTANT TO CHEMICAL CASTRATION
    Medical condition: PROSTATIC ADENOCARCINOMA CHEMICAL CASTRATION RESISTANT
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018187 HLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-002120-29 Sponsor Protocol Number: 0822-030 Start Date*: 2008-08-13
    Sponsor Name:Merck&Co.,Inc
    Full Title: A Phase III Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Odanacatib) in Prolonging Bone Metastasis-Free Survival in Men with Castration-Resistant Prostate Cancer
    Medical condition: Prevention of bone metastases in men with prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005993 Bone metastases LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-005325-23 Sponsor Protocol Number: SGB_HF_MEN Start Date*: 2014-06-20
    Sponsor Name:Rijnstate Hospital
    Full Title: Short-term Efficacy of Stellate Ganglion Block in Men to reduce Hot Flushes related to Androgen Deprivation Therapy
    Medical condition: Hot flushes due to androgen deprivation therapy
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002027-13 Sponsor Protocol Number: DPSA05 Start Date*: 2005-07-22
    Sponsor Name:Royal Marsden NHS FOundation Trust
    Full Title: A phase I/II study of docetaxel plus prednisolone plus diethylstilbestrol plus aspirin in androgen-independent prostate cancer
    Medical condition: Hormone refractory prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000160-15 Sponsor Protocol Number: MVT-601-3201 Start Date*: 2017-07-25
    Sponsor Name:Myovant Sciences GmbH
    Full Title: HERO: A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men with Advanced Prostate Cancer
    Medical condition: Androgen-sensitive advanced prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed) SE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) AT (Completed) SK (Completed) DK (Completed) FI (Completed) ES (Completed) DE (Completed) PL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004774-17 Sponsor Protocol Number: ESTO2 Start Date*: 2018-08-23
    Sponsor Name:Pirkanmaan sairaanhoitopiiri
    Full Title: Impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy – lipid metabolism as a novel biomarker to predict prostate cancer progression – phase 3, doub...
    Medical condition: Metastatic prostate cancer managed with androgen deprivation therapy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036911 Prostate cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066489 Progression of prostate cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Trial now transitioned) NO (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-020821-41 Sponsor Protocol Number: MDV3100-03 Start Date*: 2011-02-10
    Sponsor Name:Medivation, Inc., a wholly owned subsidiary of Pfizer Inc.
    Full Title: PREVAIL: A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naïve Patients with Progressive Metastatic Prostate Cancer W...
    Medical condition: Chemotherapy-Naïve Patients with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) NL (Completed) ES (Completed) SE (Completed) AT (Completed) FI (Completed) DK (Completed) SK (Completed) IT (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2005-004094-25 Sponsor Protocol Number: EGD-EC-003 Start Date*: 2006-01-05
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A phase IIIb randomized study of intermittent versus continuous androgen deprivation therapy using ELIGARD 22.5 mg 3-month depot in subjects with relapsing or locally advanced prostate cancer who a...
    Medical condition: Histologically or cytologically confirmed adenocarcinoma of the prostate (PCa) meeting the following criteria: - Locally adv. (stage T3 or T4) PCa, N0 or N+, M0 with PSA >= 5 ng/ml, or - Relapsing ...
    Disease: Version SOC Term Classification Code Term Level
    8.0 10060862 LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Completed) AT (Prematurely Ended) FI (Completed) SK (Completed) IE (Completed) HU (Completed) DE (Completed) ES (Completed) SE (Completed) GB (Completed) PT (Completed) BE (Completed) DK (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000899-15 Sponsor Protocol Number: EORTC-1531-ROG Start Date*: 2019-12-03
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: Radiotherapy and 6-month androgen deprivation therapy with or without apalutamide in Intermediate and Limited High Risk Localized Prostate Cancer: a phase III study
    Medical condition: Intermediate and Limited High Risk Localized Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001786-18 Sponsor Protocol Number: CZOL446GDE08 Start Date*: 2005-03-22
    Sponsor Name:EAU EUROPEAN ASSOCIATION OF UROLOGY
    Full Title: Effectiveness of Zometa treatment for the prevention of bone metastases in high risk prostate cancer patients. A randomized, open-label, multicenter study of the European Association of Urology (EA...
    Medical condition: Prevention of bone metastasis in high risk prostate cancer patients.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-004765-42 Sponsor Protocol Number: CZOL446GGB12 including amd 1 Start Date*: 2006-05-03
    Sponsor Name:Novartis Pharmaceuticals UK Ltd
    Full Title: An Open label Randomised, multicentre study to evaluate the efficacy of two Zometa (Zoledronic acid) schedules on bone mineral density in prostrate cancer patients undergoing Androgen deprivation T...
    Medical condition: Decreased bone mineral density in prostate cancer patients being treated with ADT
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-000314-38 Sponsor Protocol Number: 1206-HNCG Start Date*: 2014-07-28
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: A randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic, androgen receptor (AR) expre...
    Medical condition: Salivary gland cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061934 Salivary gland cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) NL (Completed) GB (GB - no longer in EU/EEA) HU (Completed) AT (Completed) GR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000512-17 Sponsor Protocol Number: 20040138 Start Date*: 2004-10-01
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Double-Blind, Placebo-controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer
    Medical condition: Bone loss in pateints undergoing androgen-deprivation therapy (ADT) for non-metastatic prostate cancer.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10049470 Bone density decreased LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Completed) HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2014-001162-10 Sponsor Protocol Number: EUOG2014-002 Start Date*: 2015-05-06
    Sponsor Name:European Uro- Oncology Group (EUOG)
    Full Title: An Exploratory Phase 2, open-label, single-arm, efficacy and imaging Study of Oral Enzalutamide (MDV3100) Androgen Receptor (AR)-Directed Therapy in Hormono-Naïve patients with Metastatic Prostate ...
    Medical condition: Patients with Metastatic Prostate Cancer who have never been treated with Androgen Deprivation Therapy
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002940-26 Sponsor Protocol Number: 212082PCR3011 Start Date*: 2013-05-24
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Me...
    Medical condition: Metastatic Hormone-Naive Prostate Cancer (mHNPC)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) FR (Completed) SE (Completed) HU (Completed) PT (Completed) FI (Completed) ES (Completed) IT (Completed) SK (Completed) DK (Completed) DE (Completed) BE (Completed) PL (Completed) BG (Completed) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2015-002590-38 Sponsor Protocol Number: 17777 Start Date*: 2016-12-14
    Sponsor Name:Bayer AG
    Full Title: A randomized, double-blind, placebo-controlled Phase III study of darolutamide (ODM-201) versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastati...
    Medical condition: Metastatic hormone-sensitive prostate cancer (mHSPC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) BE (Completed) ES (Completed) FI (Completed) DE (Completed) CZ (Completed) NL (Completed) PL (Completed) FR (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000076-37 Sponsor Protocol Number: NL72585.091.20 Start Date*: 2023-03-30
    Sponsor Name:Radboud University Medical Center
    Full Title: Lutetium-177-PSMA in Oligo-metastatic Hormone Sensitive Prostate Cancer.
    Medical condition: Oligo-metastatic adenocarcinoma of the prostate.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CY (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 18:11:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA